IP Library Granted Patent US 11,447,758
Granted Patent B2
US 11,447,758 · App. 16/536,256 · Granted Sep 20, 2022

Protein mutants that enhance the DNA cleavage activity of

Inventors: Liyang Zhang (Coralville, IA); Christopher Anthony Vakulskas (North Liberty, IA); Nicole Mary Bode (Oxford, IA); Michael Allen Collingwood (North Liberty, IA); Kristin Renee Beltz (Cedar Rapids, IA); Mark Aaron Behlke (Coralville, IA)
Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
C12N9/22C12N15/11C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,447,758
App. No.
16/536,256
Granted
Sep 20, 2022
Kind
B2
Abstract

The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.

Claims (17)

1. A CRISPR-associated protein comprising a variant of a Cas12a, wherein the variant of the Cas12a comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 472, 473 and 465.

2. The CRISPR-associated protein according to claim 1 , wherein the variant of the Cas12a consists of SEQ ID NO: 472.

3. The CRISPR-associated protein according to claim 1 , wherein the variant of the Cas12a consists of SEQ ID NO: 473.

4. The CRISPR-associated protein according to claim 1 , wherein the variant of the Cas12a consists of SEQ ID NO: 465.

5. A CRISPR ribonucleoprotein complex, comprising:

a guide RNA; and

a CRISPR-associated protein comprising a variant of a Cas12a, wherein the variant of the Cas12a comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 472, 473 and 465.

6. The CRISPR ribonucleoprotein complex of claim 5 , wherein the variant of the Cas12a consists of SEQ ID NO: 472.

7. The CRISPR ribonucleoprotein complex of claim 5 , wherein the variant of the Cas12a consists of SEQ ID NO: 473.

8. The CRISPR ribonucleoprotein complex of claim 5 , wherein the variant of the Cas12a consists of SEQ ID NO: 465.

9. A CRISPR-associated protein comprising a variant of the Cas12a—of SEQ ID NO.: 462, wherein the variant of the Cas12a comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 59-245.

10. A Cas12a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:18-22 and 24-30.

11. A CRISPR-associated protein comprising a fusion polypeptide comprising a Cas12a protein, a nuclear localization signal, optionally an amino acid linker and optionally an affinity tag,

wherein the Cas12a protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 59-245, and

wherein the nuclear localization signal comprises an amino acid sequence selected from SEQ ID NO: 475, 477, 479, 481 and 483.

12. A CRISPR-associated protein, wherein the CRISPR-associated protein is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 489 and 491.

13. A CRISPR-associated protein, wherein the CRISPR-associated protein comprises SEQ ID NO: 493.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2019
From: ZHANG, LIYANG; VAKULSKAS, CHRISTOPHER ANTHONY; BODE, NICOLE MARY; COLLINGWOOD, MICHAEL ALLEN; BELTZ, KRISTIN RENEE; BEHLKE, MARK AARON
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 051200/0078 →
Continuity (4)
Provisional Application 62870268 · Jul 3, 2019
Provisional Application 62749607 · Oct 23, 2018
Provisional Application 62716138 · Aug 8, 2018
Related Publication 20200109382A1 · Apr 9, 2020
Cited By (1)
US 12,454,684